Cardiogenic Shock Clinical Trials

22 recruiting

Frequently Asked Questions

Common questions about Cardiogenic Shock clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Not Applicable

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Heart FailureCardiogenic ShockAmbulatory Hemodynamic Monitoring
Inova Health Care Services40 enrolled1 locationNCT04419480
Recruiting
Not Applicable

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

Heart FailureCardiogenic ShockAcute Myocardial Infarction (AMI)
Magenta Medical Ltd.10 enrolled5 locationsNCT07293923
Recruiting
Phase 2

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

Heart FailureCardiomyopathiesCardiogenic Shock+1 more
Stanford University50 enrolled5 locationsNCT06080074
Recruiting
Not Applicable

Pulmonary Artery Catheter in Cardiogenic Shock Trial

Heart FailureCardiogenic Shock
Tufts Medical Center400 enrolled1 locationNCT05485376
Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

SepsisLiver Transplant; ComplicationsPancreatitis+15 more
CytoSorbents, Inc3,000 enrolled28 locationsNCT05146336
Recruiting
Not Applicable

Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI

Cardiogenic ShockCoronary Artery DiseaseChronic Heart Failure+4 more
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation100 enrolled1 locationNCT07149714
Recruiting
Phase 3

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

Cardiogenic Shock
Pr Bruno LEVY610 enrolled28 locationsNCT04020263
Recruiting

Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock

Acute Coronary SyndromeCardiogenic Shock
University of Minnesota200 enrolled1 locationNCT05426083
Recruiting
Early Phase 1

Cardiac Power Output in Cardiogenic Shock Patients

Heart FailureCardiogenic Shock
University of Chicago5 enrolled1 locationNCT05700617
Recruiting
Phase 3

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Cardiogenic Shock
Central Hospital, Nancy, France164 enrolled8 locationsNCT05879276
Recruiting

Cardiogenic Shock Working Group Registry

Cardiogenic Shock
Tufts Medical Center5,000 enrolled16 locationsNCT04682483
Recruiting

Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure

Heart FailureCardiogenic ShockMuscle Atrophy+1 more
Tufts Medical Center60 enrolled1 locationNCT06253104
Recruiting

Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

Heart FailureCardiogenic ShockExtracorporeal Membrane Oxygenation+3 more
Xiaotong Hou534 enrolled1 locationNCT06862700
Recruiting

Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry)

Acute Coronary SyndromeCardiogenic ShockAcute Heart Failure+1 more
Federico II University5,000 enrolled1 locationNCT06162247
Recruiting

Pharmacological and Mechanical Support Approaches in the Management of Acute Heart Failure in the Regional Network Model for the Management of Cardiogenic Shock

Cardiogenic ShockAcute Coronary Event
IRCCS Azienda Ospedaliero-Universitaria di Bologna500 enrolled1 locationNCT06827314
Recruiting
Not Applicable

Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock

Cardiogenic ShockAcute Myocardial Infarction
Assistance Publique - Hôpitaux de Paris400 enrolled1 locationNCT04184635
Recruiting

Role of Candidate Proteins in Capillary Leakage During Acute Circulatory Failure

Cardiogenic ShockSeptic ShockPostresuscitation Disease
Assistance Publique - Hôpitaux de Paris380 enrolled1 locationNCT05586282
Recruiting
Phase 2

REMAP ECMO - Beta Receptor Modulation Trial

Heart FailureCardiogenic Shock
Erasmus Medical Center20 enrolled1 locationNCT06522594
Recruiting

China Extracorporeal Life Support Registry

Heart FailureAcute Respiratory FailureCardiogenic Shock+2 more
Beijing Anzhen Hospital20,000 enrolled1 locationNCT04158479
Recruiting

NIVIA-Hemodynamics

Heart FailureCardiogenic ShockShock+1 more
University Health Network, Toronto100 enrolled1 locationNCT06330597